Non-Hodgkin Lymphoma Clinical Trials
Non-Hodgkin lymphoma clinical trials give patients opportunities to access the latest treatments before those options are available in other settings. For instance, novel immunotherapies and chemotherapy medications are first evaluated in clinical trials before being used in traditional settings. As a result, trial participants are among some of the first to benefit from new treatments as their effectiveness is studied by lymphoma researchers.
Moffitt Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, conducts hundreds of clinical trials each year, some of which focus on non-Hodgkin lymphoma diagnosis and treatment options. Recent trials have centered on:
- New strategies for improving response rates to stem cell transplantation
- Novel maintenance therapies for use after initial non-Hodgkin lymphoma treatment
- Tumor-suppressing immunotherapies and biologic treatments
With a skilled research faculty and support team, as well as designated programs focusing on chemical biology and molecular medicine, immunology, cancer biology, health outcomes and cancer epidemiology, Moffitt is committed to staying at the forefront of scientific advances for lymphoma diagnosis and treatment. And, by taking a bench-to-bedside approach, we apply what we learn in the lab to our day-to-day patient care, fast-tracking laboratory successes into new treatments for our patients and others across the nation.
Moffitt Cancer Center can help patients explore their options for accessing the latest advances in non-Hodgkin lymphoma treatment. To learn more about our clinical trials for non-Hodgkin lymphoma, call 1-888-663-3488 or submit a new patient registration form online. Participation does not require a physician’s referral.